SS Innovations International, Inc. (SSII) - 10-K Summary
Business Context and Reporting Period
Company: SS Innovations International, Inc. (SSII)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: SSII is a commercial-stage surgical robotics company focused on the SSi Mantra system, designed to democratize access to robotic surgery in underserved markets. The company designs, manufactures, and markets the SSi Mantra and SSi Mantra 3 systems, along with instruments (SSi Mudra) and accessories.
Key Milestones (2024):
- Installed 62 systems globally (58 in India, 4 overseas) as of December 31, 2024.
- Performed over 2,759 robotic surgeries globally using the SSi Mantra.
- Received regulatory approval for telesurgery and tele-proctoring from India's CDSCO.
- Expanded into Indonesia, Nepal, Ecuador, and Guatemala.
- Introduced the next-generation SSi Mantra 3 in June 2024.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $20,649,528 | $5,875,314 |
| Gross Profit | $8,452,366 | $725,528 |
| Gross Margin | 40.9% | 12.3% |
| Net Loss | $(19,151,197) | $(20,878,292) |
| Operating Cash Flow | $(9,503,030) | $(15,361,645) |
| Cash & Restricted Cash | $6,623,535 | $7,087,845 |
| Total Assets | $42,385,213 | $31,515,994 |
| Total Liabilities | $28,928,110 | $11,797,916 |
| Shareholders' Equity | $13,457,103 | $19,718,078 |
Note: Stock compensation expense was $14.34 million in 2024 compared to $9.72 million in 2023, significantly impacting net loss.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 251% year-over-year, driven by the sale of 36 surgical robotic systems (up from prior year) and increased instrument sales. System sales accounted for $19.46 million of total revenue.
- Profitability: Gross profit improved significantly to $8.45 million (40.9% margin) from $0.73 million (12.3% margin), reflecting better cost management and scale.
- Net Loss Reduction: Net loss decreased by approximately $1.7 million to $19.15 million, primarily due to the increase in gross profit, partially offset by higher stock compensation expenses.
- Liabilities: Total liabilities more than doubled to $28.9 million, driven by an increase in bank overdraft facilities ($8.0 million) and notes payable ($7.5 million) to fund working capital.
- Inventory: Inventory increased to $10.2 million from $7.0 million to support revenue growth and expansion.
Guidance, Outlook, Risks, and Contingencies
Outlook & Strategy:
- Regulatory Path: The company is preparing an Investigational Device Exemption (IDE) application for the U.S. FDA, expecting to start the U.S. IDE study in Q3 2025. CE certification discussions for the EU are ongoing, with a submission expected in Q2 2025.
- Expansion: Focus remains on underserved markets (India, Asia, Africa, Latin America) before expanding to the U.S. and EU. The company plans to raise additional capital in 2025 to scale operations.
- Product Pipeline: Development continues on the SSi Mantra 3, mobile tele-surgical units (SSi MantraM), and new instruments like the NADI automated coronary connector.
- Going Concern: The filing includes a "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows. The company relies on debt and equity financing to meet obligations.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including inadequate controls for U.S. GAAP application and lack of segregation of duties. Remediation efforts are underway.
- Regulatory Approval: No assurance exists regarding the timing or success of FDA or CE approvals, which are critical for U.S. and EU market entry.
- Litigation: An ex-shareholder of a subsidiary (Otto Pvt Ltd.) has commenced litigation in the Bahamas regarding share ownership. The company believes the outcome will be favorable and has an indemnification agreement with the CEO.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($6.6M) and restricted cash against the burn rate and upcoming capital needs for FDA trials and manufacturing expansion.
- Debt Structure: Review the terms of the $7.5M in notes payable and $8.0M bank overdraft, including interest rates, maturity dates, and conversion rights (many are convertible notes).
- Revenue Recognition: Scrutinize the revenue recognition policies for deferred payment sales and pay-per-procedure models, as these were cited as areas of material weakness in internal controls.
- Regulatory Timeline: Monitor the progress of the FDA IDE application and the expected Q3 2025 study start date.
- Stock Compensation: Assess the impact of the $14.3M stock compensation expense on future dilution and cash flow, noting the significant grants made in late 2024.
- Internal Control Remediation: Track the implementation of the new cloud-based ERP system and the remediation of material weaknesses in financial reporting.